JPWO2021167012A1 - - Google Patents

Info

Publication number
JPWO2021167012A1
JPWO2021167012A1 JP2022501978A JP2022501978A JPWO2021167012A1 JP WO2021167012 A1 JPWO2021167012 A1 JP WO2021167012A1 JP 2022501978 A JP2022501978 A JP 2022501978A JP 2022501978 A JP2022501978 A JP 2022501978A JP WO2021167012 A1 JPWO2021167012 A1 JP WO2021167012A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022501978A
Other languages
Japanese (ja)
Other versions
JPWO2021167012A5 (https=
JP7642212B2 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021167012A1 publication Critical patent/JPWO2021167012A1/ja
Publication of JPWO2021167012A5 publication Critical patent/JPWO2021167012A5/ja
Application granted granted Critical
Publication of JP7642212B2 publication Critical patent/JP7642212B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022501978A 2020-02-18 2021-02-18 神経機能調節用組成物 Active JP7642212B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020025496 2020-02-18
JP2020025496 2020-02-18
PCT/JP2021/006166 WO2021167012A1 (ja) 2020-02-18 2021-02-18 神経機能調節用組成物

Publications (3)

Publication Number Publication Date
JPWO2021167012A1 true JPWO2021167012A1 (https=) 2021-08-26
JPWO2021167012A5 JPWO2021167012A5 (https=) 2023-04-24
JP7642212B2 JP7642212B2 (ja) 2025-03-10

Family

ID=77392155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022501978A Active JP7642212B2 (ja) 2020-02-18 2021-02-18 神経機能調節用組成物

Country Status (2)

Country Link
JP (1) JP7642212B2 (https=)
WO (1) WO2021167012A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113694054A (zh) * 2021-09-29 2021-11-26 深圳市人民医院 一种化合物4-o-阿魏酰-5-o-咖啡酰奎宁酸甲酯在药物中的应用
JP7610209B2 (ja) * 2022-10-13 2025-01-08 国立大学法人 筑波大学 ミトコンドリア活性向上用組成物

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014159A1 (en) * 2002-08-07 2004-02-19 Queen Bioactives Pty Ltd Method of lowering glycaemic index of foods
JP2005518381A (ja) * 2001-12-19 2005-06-23 ザ キグリー コーポレーション 抹消神経・血管疾患の治療方法
JP2015528448A (ja) * 2012-08-28 2015-09-28 ザ プロダクト メーカーズ (オーストラリア) プロプライエタリー リミテッド 抽出方法
JP2016531909A (ja) * 2013-08-14 2016-10-13 テ ファ ファーマシューティカル カンパニー リミテッド フラボン−6−c−グルコース誘導体を有効成分として含有する神経精神疾患治療又は予防用薬学的組成物
KR101766233B1 (ko) * 2016-06-10 2017-08-08 한약진흥재단 루테올린 5-글루코사이드를 유효성분으로 포함하는 신경 질환의 예방 또는 치료용 조성물
JP2018039797A (ja) * 2016-09-02 2018-03-15 花王株式会社 脳機能改善剤
WO2018199109A1 (ja) * 2017-04-24 2018-11-01 学校法人産業医科大学 神経変性疾患治療剤
WO2018207791A1 (ja) * 2017-05-12 2018-11-15 花王株式会社 Arc発現促進剤
WO2018207790A1 (ja) * 2017-05-12 2018-11-15 花王株式会社 アミロイドβ分解排出促進剤
CN108904488A (zh) * 2018-04-24 2018-11-30 东北师范大学 一种化合物在降低蛋白聚积治疗老年痴呆方面的应用
CN109198628A (zh) * 2018-10-10 2019-01-15 陶燃 一种治疗抑郁症及焦虑症的组合物及其用途
WO2019040989A1 (en) * 2017-08-31 2019-03-07 The Product Makers (Australia) Pty Ltd IMPROVING THE TASTE OF CONSUMER PRODUCTS
CN110507645A (zh) * 2019-09-24 2019-11-29 广东工业大学 木犀草素的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3793779B2 (ja) * 2000-11-27 2006-07-05 沖縄県 サトウキビポリフェノール含有物の製造方法
JP4199448B2 (ja) * 2001-10-30 2008-12-17 琉球セメント株式会社 サトウキビポリフェノール含有物を有効成分とする医薬剤並びにその用途
JP6289218B2 (ja) * 2014-03-31 2018-03-07 大阪瓦斯株式会社 PPARα活性組成物の活性化方法

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518381A (ja) * 2001-12-19 2005-06-23 ザ キグリー コーポレーション 抹消神経・血管疾患の治療方法
WO2004014159A1 (en) * 2002-08-07 2004-02-19 Queen Bioactives Pty Ltd Method of lowering glycaemic index of foods
JP2015528448A (ja) * 2012-08-28 2015-09-28 ザ プロダクト メーカーズ (オーストラリア) プロプライエタリー リミテッド 抽出方法
JP2016531909A (ja) * 2013-08-14 2016-10-13 テ ファ ファーマシューティカル カンパニー リミテッド フラボン−6−c−グルコース誘導体を有効成分として含有する神経精神疾患治療又は予防用薬学的組成物
KR101766233B1 (ko) * 2016-06-10 2017-08-08 한약진흥재단 루테올린 5-글루코사이드를 유효성분으로 포함하는 신경 질환의 예방 또는 치료용 조성물
JP2018039797A (ja) * 2016-09-02 2018-03-15 花王株式会社 脳機能改善剤
WO2018199109A1 (ja) * 2017-04-24 2018-11-01 学校法人産業医科大学 神経変性疾患治療剤
WO2018207791A1 (ja) * 2017-05-12 2018-11-15 花王株式会社 Arc発現促進剤
WO2018207790A1 (ja) * 2017-05-12 2018-11-15 花王株式会社 アミロイドβ分解排出促進剤
WO2019040989A1 (en) * 2017-08-31 2019-03-07 The Product Makers (Australia) Pty Ltd IMPROVING THE TASTE OF CONSUMER PRODUCTS
CN108904488A (zh) * 2018-04-24 2018-11-30 东北师范大学 一种化合物在降低蛋白聚积治疗老年痴呆方面的应用
CN109198628A (zh) * 2018-10-10 2019-01-15 陶燃 一种治疗抑郁症及焦虑症的组合物及其用途
CN110507645A (zh) * 2019-09-24 2019-11-29 广东工业大学 木犀草素的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
前田 剛希他: "サトウキビ梢頭部の抗酸化能および抗酸化成分の同定", 沖縄県農業研究センター研究報告, vol. 第4号, JPN6021014347, 2010, pages 52 - 57, ISSN: 0005361197 *

Also Published As

Publication number Publication date
WO2021167012A1 (ja) 2021-08-26
JP7642212B2 (ja) 2025-03-10

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
JPWO2021167012A1 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011610A2 (https=)
BR112023011539A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250217

R150 Certificate of patent or registration of utility model

Ref document number: 7642212

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02